LTC2785706I2 - Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui - Google Patents

Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui

Info

Publication number: LTC2785706I2
Authority: LT; Lithuania
Prior art keywords: pyridines; receptor; phenyl; substituted; treatment
Prior art date: 2011-11-29

Application number

LTPA2020510C

Other languages

English (en)

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-29

Filing date

2020-06-16

Publication date

2023-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48094815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2785706(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-06-16 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2020-07-10 Publication of LTPA2020510I1 publication Critical patent/LTPA2020510I1/lt

2023-07-10 Publication of LTC2785706I2 publication Critical patent/LTC2785706I2/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LTPA2020510C 2011-11-29 2020-06-16 Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui LTC2785706I2 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161564537P	2011-11-29	2011-11-29
US13/478,361 US8426450B1 (en)	2011-11-29	2012-05-23	Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en)	2011-11-29	2012-11-28	Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Publications (2)

Publication Number	Publication Date
LTPA2020510I1 LTPA2020510I1 (lt)	2020-07-10
LTC2785706I2 true LTC2785706I2 (lt)	2023-07-10

Family

ID=48094815

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP12798549.7T LT2785706T (lt)	2011-11-29	2012-11-28	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
LTPA2020510C LTC2785706I2 (lt)	2011-11-29	2020-06-16	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP12798549.7T LT2785706T (lt)	2011-11-29	2012-11-28	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui

Country Status (51)

Country	Link
US (7)	US8426450B1 (lt)
EP (1)	EP2785706B1 (lt)
JP (3)	JP5635708B2 (lt)
KR (1)	KR101979050B1 (lt)
CN (6)	CN106986822B (lt)
AP (1)	AP2014007729A0 (lt)
AR (1)	AR089019A1 (lt)
AU (1)	AU2012346133B2 (lt)
BR (1)	BR112014012878B1 (lt)
CA (1)	CA2850644C (lt)
CL (1)	CL2014001280A1 (lt)
CO (1)	CO6990728A2 (lt)
CR (1)	CR20140312A (lt)
CY (2)	CY1118416T1 (lt)
DK (1)	DK2785706T3 (lt)
DO (1)	DOP2014000115A (lt)
EA (1)	EA026553B1 (lt)
EC (1)	ECSP14003642A (lt)
ES (1)	ES2603958T3 (lt)
FI (1)	FIC20200022I1 (lt)
FR (1)	FR20C1029I2 (lt)
GE (1)	GEP201706695B (lt)
GT (1)	GT201400102A (lt)
HK (1)	HK1199030A1 (lt)
HR (1)	HRP20161708T1 (lt)
HU (2)	HUE032288T2 (lt)
IL (1)	IL232859B (lt)
IN (1)	IN2014CN04907A (lt)
JO (1)	JO3202B1 (lt)
LT (2)	LT2785706T (lt)
MA (1)	MA35836B1 (lt)
MD (1)	MD4539C1 (lt)
ME (1)	ME02561B (lt)
MX (1)	MX2014006423A (lt)
MY (1)	MY165514A (lt)
NI (1)	NI201400043A (lt)
NL (1)	NL301047I2 (lt)
PE (1)	PE20141421A1 (lt)
PH (1)	PH12014501199B1 (lt)
PL (1)	PL2785706T3 (lt)
PT (1)	PT2785706T (lt)
RS (1)	RS55448B1 (lt)
SG (1)	SG11201402044XA (lt)
SI (1)	SI2785706T1 (lt)
SM (2)	SMT201600467T1 (lt)
TN (1)	TN2014000165A1 (lt)
TW (1)	TWI638806B (lt)
UA (1)	UA115136C2 (lt)
UY (1)	UY34472A (lt)
WO (1)	WO2013082102A1 (lt)
ZA (1)	ZA201404787B (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012024616A1 (en)	2010-08-19	2012-02-23	Buck Institute For Age Research	Methods of treating miild cognitive impairment (mci) and related discorders
EP2648930B1 (en)	2010-12-07	2019-11-06	Allison Transmission, Inc.	Energy storage system for hybrid electric vehicle
KR20150055094A (ko)	2011-06-22	2015-05-20	퍼듀 퍼머 엘피	디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
AU2014347644B2 (en)	2013-11-08	2018-06-14	Kissei Pharmaceutical Co., Ltd.	Carboxymethyl piperidine derivative
EP3140007A1 (en) *	2014-05-05	2017-03-15	Apicore US LLC	Methods of making netupitant and intermediates thereof
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
TW201613888A (en) *	2014-09-26	2016-04-16	Helsinn Healthcare Sa	Crystalline forms of an NK-1 antagonist
US9782408B2 (en)	2014-10-06	2017-10-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN105061303A (zh) *	2015-08-03	2015-11-18	成都欣捷高新技术开发有限公司	一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) *	2015-10-06	2018-06-26	Helsinn Healthcare Sa	Crystalline forms of fosnetupitant
CN106892864A (zh) *	2015-12-21	2017-06-27	上海科胜药物研发有限公司	一种奈妥皮坦游离碱的晶型a及其制备方法
ES2946970T3 (es)	2016-03-31	2023-07-28	Vertex Pharma	Regulador de conductancia transmembrana de moduladores de fibrosis quística
EP3435980B1 (en) *	2016-06-06	2019-11-13	Helsinn Healthcare SA	Physiologically balanced injectable formulations of fosnetupitant
JOP20190042B1 (ar)	2016-09-30	2021-08-17	Vertex Pharma	مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
PE20241131A1 (es)	2016-12-09	2024-05-24	Vertex Pharma	Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
CN108619525B (zh) *	2017-03-15	2020-12-29	和龙	奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49524A (fr)	2017-06-30	2021-05-26	Chase Therapeutics Corp	Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
EP3661915B1 (en)	2017-08-02	2022-03-09	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
CN107698500A (zh) *	2017-10-17	2018-02-16	扬子江药业集团四川海蓉药业有限公司	一种奈妥匹坦的制备方法
MA50400A (fr)	2017-10-19	2020-08-26	Vertex Pharma	Formes cristallines et compositions de modulateurs de cftr
NZ765171A (en)	2017-12-08	2024-12-20	Vertex Pharma	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
EP3737378B1 (en) *	2018-01-12	2023-04-19	Orion Corporation	Palonosetron eye drops for the treatment or prevention of nausea and vomiting
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) *	2019-04-18	2022-10-19	株式会社島津製作所	培地処理システム及び培地処理方法
CN112174881B (zh) *	2019-07-04	2022-06-21	上海森辉医药有限公司	一种奈妥匹坦的衍生物及其制备方法
CN112778370A (zh) *	2019-11-06	2021-05-11	扬子江药业集团江苏海慈生物药业有限公司	一种制备福奈妥匹坦的方法
JP2023519570A (ja)	2020-04-03	2023-05-11	ネッレセラピューティクスリミテッド	新規使用
CA3177477A1 (en)	2020-06-02	2021-12-09	Nerre Therapeutics Limited	Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en)	2021-12-21	2024-09-24	Slayback Pharma Llc	Stable liquid compositions of netupitant and palonosetron

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE261730T1 (de) *	1997-12-31	2004-04-15	Univ Kansas	Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
DK1394150T3 (da) *	1999-02-24	2011-03-21	Hoffmann La Roche	4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6303790B1 (en)	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
EP1103545B1 (en) *	1999-11-29	2003-11-05	F. Hoffmann-La Roche Ag	2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6362172B2 (en) *	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
KR100501608B1 (ko)	2000-07-14	2005-07-18	에프. 호프만-라 로슈 아게	4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) *	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
DK1349541T3 (da)	2000-12-14	2007-01-08	Hoffmann La Roche	Selvemulgerende lipidmatrix (SELM)
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) *	2004-03-15	2010-06-29	Bristol-Myers Squibb Company	Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DK1863767T3 (da) *	2005-03-23	2009-05-04	Hoffmann La Roche	Metabolitter til NK-I-antagonister til emesis
CN101282979B (zh) *	2005-09-13	2011-09-21	卫材R&D管理有限公司	稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
GB0808747D0 (en) *	2008-05-14	2008-06-18	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
UA108077C2 (xx) *	2009-07-02	2015-03-25		Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
PT2361090E (pt) *	2009-11-18	2014-09-03	Helsinn Healthcare Sa	Composições para o tratamento centrado de náusea e vómito mediado
AU2010339689B2 (en) *	2010-01-07	2015-02-19	Alkermes Pharma Ireland Limited	Quaternary ammonium salt prodrugs
DK2646035T3 (en) *	2010-12-02	2016-05-30	Univ Kansas	PRO-DRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDINE-2 (1H) -ON AND DERIVATIVES THEREOF
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
CN104718188B (zh)	2012-05-22	2018-08-21	基因泰克公司	N-取代的苯甲酰胺类及其在治疗疼痛中的用途

2012
- 2012-05-23 US US13/478,361 patent/US8426450B1/en active Active
- 2012-11-19 JO JOP/2012/0348A patent/JO3202B1/ar active
- 2012-11-28 MX MX2014006423A patent/MX2014006423A/es unknown
- 2012-11-28 PE PE2014000630A patent/PE20141421A1/es active IP Right Grant
- 2012-11-28 PT PT127985497T patent/PT2785706T/pt unknown
- 2012-11-28 MD MDA20140059A patent/MD4539C1/ro active IP Right Grant
- 2012-11-28 CA CA2850644A patent/CA2850644C/en active Active
- 2012-11-28 HU HUE12798549A patent/HUE032288T2/hu unknown
- 2012-11-28 EP EP12798549.7A patent/EP2785706B1/en active Active
- 2012-11-28 UA UAA201407175A patent/UA115136C2/uk unknown
- 2012-11-28 RS RS20161103A patent/RS55448B1/sr unknown
- 2012-11-28 CN CN201710324776.2A patent/CN106986822B/zh active Active
- 2012-11-28 GE GEAP201213508A patent/GEP201706695B/en unknown
- 2012-11-28 KR KR1020147017431A patent/KR101979050B1/ko active IP Right Grant
- 2012-11-28 BR BR112014012878-2A patent/BR112014012878B1/pt active IP Right Grant
- 2012-11-28 AU AU2012346133A patent/AU2012346133B2/en active Active
- 2012-11-28 WO PCT/US2012/066778 patent/WO2013082102A1/en active Application Filing
- 2012-11-28 SM SM20160467T patent/SMT201600467T1/it unknown
- 2012-11-28 CN CN202110222524.5A patent/CN112961104A/zh active Pending
- 2012-11-28 MY MYPI2014001505A patent/MY165514A/en unknown
- 2012-11-28 LT LTEP12798549.7T patent/LT2785706T/lt unknown
- 2012-11-28 CN CN201280058800.8A patent/CN104053652A/zh active Pending
- 2012-11-28 ES ES12798549.7T patent/ES2603958T3/es active Active
- 2012-11-28 DK DK12798549.7T patent/DK2785706T3/en active
- 2012-11-28 CN CN202010607408.0A patent/CN111662330B/zh active Active
- 2012-11-28 PL PL12798549T patent/PL2785706T3/pl unknown
- 2012-11-28 CN CN201610957278.7A patent/CN106518924B/zh active Active
- 2012-11-28 IN IN4907CHN2014 patent/IN2014CN04907A/en unknown
- 2012-11-28 JP JP2013555647A patent/JP5635708B2/ja active Active
- 2012-11-28 EA EA201400624A patent/EA026553B1/ru unknown
- 2012-11-28 ME MEP-2016-283A patent/ME02561B/me unknown
- 2012-11-28 UY UY0001034472A patent/UY34472A/es active IP Right Grant
- 2012-11-28 SG SG11201402044XA patent/SG11201402044XA/en unknown
- 2012-11-28 CN CN202110222556.5A patent/CN112979543B/zh active Active
- 2012-11-28 AP AP2014007729A patent/AP2014007729A0/xx unknown
- 2012-11-28 SI SI201230810A patent/SI2785706T1/sl unknown
- 2012-11-29 TW TW101144681A patent/TWI638806B/zh active
- 2012-11-29 AR ARP120104473A patent/AR089019A1/es active IP Right Grant
2013
- 2013-04-17 US US13/864,381 patent/US8895586B2/en active Active
2014
- 2014-04-18 TN TNP2014000165A patent/TN2014000165A1/en unknown
- 2014-05-13 NI NI201400043A patent/NI201400043A/es unknown
- 2014-05-15 CL CL2014001280A patent/CL2014001280A1/es unknown
- 2014-05-26 GT GT201400102A patent/GT201400102A/es unknown
- 2014-05-28 IL IL232859A patent/IL232859B/en active IP Right Grant
- 2014-05-28 PH PH12014501199A patent/PH12014501199B1/en unknown
- 2014-05-28 DO DO2014000115A patent/DOP2014000115A/es unknown
- 2014-06-05 EC ECIEPI20143642A patent/ECSP14003642A/es unknown
- 2014-06-20 CO CO14134660A patent/CO6990728A2/es unknown
- 2014-06-25 MA MA37152A patent/MA35836B1/fr unknown
- 2014-06-27 ZA ZA2014/04787A patent/ZA201404787B/en unknown
- 2014-06-27 CR CR20140312A patent/CR20140312A/es unknown
- 2014-10-15 JP JP2014210716A patent/JP6023146B2/ja active Active
- 2014-12-15 HK HK14112566.3A patent/HK1199030A1/zh unknown
2016
- 2016-02-25 JP JP2016034427A patent/JP6074083B2/ja active Active
- 2016-06-28 US US15/194,984 patent/US9908907B2/en active Active
- 2016-12-09 CY CY20161101278T patent/CY1118416T1/el unknown
- 2016-12-13 HR HRP20161708TT patent/HRP20161708T1/hr unknown
- 2016-12-22 SM SM201600467T patent/SMT201600467B/it unknown
2018
- 2018-01-18 US US15/874,325 patent/US10208073B2/en active Active
- 2018-12-21 US US16/228,835 patent/US10717721B2/en active Active
2020
- 2020-06-08 US US16/896,135 patent/US11312698B2/en active Active
- 2020-06-16 LT LTPA2020510C patent/LTC2785706I2/lt unknown
- 2020-06-18 NL NL301047C patent/NL301047I2/nl unknown
- 2020-06-24 FI FIC20200022C patent/FIC20200022I1/fi unknown
- 2020-07-03 CY CY2020017C patent/CY2020017I1/el unknown
- 2020-07-03 FR FR20C1029C patent/FR20C1029I2/fr active Active
- 2020-08-18 HU HUS2000032C patent/HUS2000032I1/hu unknown
2022
- 2022-03-21 US US17/699,522 patent/US12071421B2/en active Active

Also Published As

Publication number	Publication date
PT2785706T (pt)	2016-12-16
NI201400043A (es)	2015-09-21
CN112961104A (zh)	2021-06-15
IL232859A0 (en)	2014-07-31
US10717721B2 (en)	2020-07-21
UA115136C2 (uk)	2017-09-25
NL301047I2 (nl)	2023-08-01
AU2012346133B2 (en)	2016-10-06
ECSP14003642A (es)	2015-12-31
EP2785706A1 (en)	2014-10-08
JP5635708B2 (ja)	2014-12-03
CA2850644A1 (en)	2013-06-06
US20190177296A1 (en)	2019-06-13
ME02561B (me)	2017-02-20
WO2013082102A1 (en)	2013-06-06
BR112014012878A2 (pt)	2017-06-13
JP2015017121A (ja)	2015-01-29
TN2014000165A1 (en)	2015-09-30
EA201400624A1 (ru)	2015-01-30
FR20C1029I2 (fr)	2023-12-29
MA35836B1 (fr)	2014-12-01
PE20141421A1 (es)	2014-10-03
MD4539B1 (ro)	2017-12-31
JP2014507446A (ja)	2014-03-27
MX2014006423A (es)	2014-09-08
DK2785706T3 (en)	2016-12-12
JP6074083B2 (ja)	2017-02-01
HRP20161708T1 (hr)	2017-02-10
CN104053652A (zh)	2014-09-17
CR20140312A (es)	2014-08-27
BR112014012878B1 (pt)	2022-05-31
CO6990728A2 (es)	2014-07-10
IN2014CN04907A (lt)	2015-09-18
KR20140103991A (ko)	2014-08-27
MD20140059A2 (en)	2014-11-30
JP6023146B2 (ja)	2016-11-09
ES2603958T3 (es)	2017-03-02
NZ623746A (en)	2016-07-29
SI2785706T1 (sl)	2017-01-31
US20180194788A1 (en)	2018-07-12
TW201331181A (zh)	2013-08-01
AP2014007729A0 (en)	2014-06-30
US20130231315A1 (en)	2013-09-05
US8895586B2 (en)	2014-11-25
JO3202B1 (ar)	2018-03-08
TWI638806B (zh)	2018-10-21
KR101979050B1 (ko)	2019-05-15
US10208073B2 (en)	2019-02-19
ZA201404787B (en)	2015-12-23
PH12014501199A1 (en)	2014-09-08
FIC20200022I1 (fi)	2020-06-24
PH12014501199B1 (en)	2014-09-08
FR20C1029I1 (fr)	2020-10-02
US8426450B1 (en)	2013-04-23
MD4539C1 (ro)	2018-07-31
LT2785706T (lt)	2016-12-12
CN106518924B (zh)	2019-10-08
US9908907B2 (en)	2018-03-06
CY1118416T1 (el)	2017-06-28
IL232859B (en)	2018-01-31
CA2850644C (en)	2020-08-11
BR112014012878A8 (pt)	2021-06-15
CN106518924A (zh)	2017-03-22
CN111662330B (zh)	2023-05-12
CN111662330A (zh)	2020-09-15
US20220401463A1 (en)	2022-12-22
EP2785706B1 (en)	2016-09-14
SMT201600467B (it)	2017-03-08
RS55448B1 (sr)	2017-04-28
HUE032288T2 (hu)	2017-09-28
HK1199030A1 (zh)	2015-06-19
NL301047I1 (lt)	2020-06-24
CN106986822A (zh)	2017-07-28
US20170050993A1 (en)	2017-02-23
HUS2000032I1 (hu)	2020-09-28
MY165514A (en)	2018-03-28
CN112979543B (zh)	2024-09-24
GEP201706695B (en)	2017-07-10
DOP2014000115A (es)	2014-07-15
CN106986822B (zh)	2020-04-21
SG11201402044XA (en)	2014-09-26
US11312698B2 (en)	2022-04-26
AU2012346133A1 (en)	2014-04-17
CL2014001280A1 (es)	2014-11-07
EA026553B1 (ru)	2017-04-28
JP2016147868A (ja)	2016-08-18
CY2020017I2 (el)	2020-11-25
LTPA2020510I1 (lt)	2020-07-10
UY34472A (es)	2013-06-28
SMT201600467T1 (it)	2017-03-08
CN112979543A (zh)	2021-06-18
US20200399240A1 (en)	2020-12-24
CY2020017I1 (el)	2020-11-25
AR089019A1 (es)	2014-07-23
US12071421B2 (en)	2024-08-27
PL2785706T3 (pl)	2017-03-31
GT201400102A (es)	2015-12-07

Publication	Publication Date	Title
LTC2785706I2 (lt)	2023-07-10	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
HK1195311A1 (zh)	2014-11-07	用於治療變性疾病和炎性疾病的新化合物
LT3470063T (lt)	2025-02-10	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
LT2887944T (lt)	2022-01-10	Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
EP2782540A4 (en)	2015-07-29	CHAIR WITH ROLLERS
LT2558105T (lt)	2020-02-10	Bardoksolono metilas, skirtas nutukimo gydymui
EP2673286A4 (en)	2015-01-21	THERAPEUTIC COMPOUNDS
HUE043171T2 (hu)	2019-08-28	Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
DK2701697T3 (da)	2020-06-29	Oxidative nethindesygdomme
BR112013033974A2 (pt)	2017-02-14	terapia de combinação
DK2760886T3 (da)	2019-12-09	Immunocytokin-kombinationsterapi
FI20115876A0 (fi)	2011-09-06	Yhdistelmähoito
DK2627345T3 (da)	2014-09-01	Formuleringer til behandling af sygdomme i de øvre luftveje
IL231092A0 (en)	2014-03-31	Treatment of rhinitis
LT3292875T (lt)	2020-08-25	Kompozicijos ir būdai, skirti ligų gydymui
CO6900134A2 (es)	2014-03-20	Tratamiento de mieloma múltiple
BR112013022820A2 (pt)	2016-12-06	método de tratamento
LTPA2020511I1 (lt)	2020-07-27	Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
EP2718255A4 (en)	2015-01-14	QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
LT2782602T (lt)	2019-10-10	Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
PL2718434T3 (pl)	2018-08-31	Kompozycje i sposoby leczenia choroby trzewnej
CO6880064A2 (es)	2014-02-28	Métodos terapéuticos
IL229081A0 (en)	2013-12-31	Isoxazolines as therapeutic agents